Exact Mass: 301.199

(1R,9R,13R)-1,13-Dimethyl-10-[[(2R)-oxolan-2-yl]methyl]-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol

C19H27NO2 (301.2042)

1-[(5-Methoxy-3-indolylidene)methylamino]-2-pentylguanidine

C16H23N5O (301.1903)

1-[[(Z)-[5-(Hydroxymethyl)indol-3-ylidene]methyl]amino]-2-pentylguanidine

C16H23N5O (301.1903)

Phormidinine B

C19H27NO2 (301.2042)

DC 14

C14H27N3O4 (301.2001)

SDZ HTF 919

C16H23N5O (301.1903)

(E,E)-2,4-decadienoic acid p-methoxyphenethylamide

C19H27NO2 (301.2042)

C19H27NO2

C19H27NO2 (301.2042)

Haminol 4|Haminol-4

C19H27NO2 (301.2042)

CHEMBL2229478

C19H27NO2 (301.2042)

9-Hydroxy-1-Methyl-2-nonyl-4(1H)-quinolinone

C19H27NO2 (301.2042)

2,9-Pentadecadiene-12,14-diynoic acid(2-hydroxyisobutyl)amide|pentadeca-2t,9c-dien-12,14-diynoic acid (2-hydroxyisobutyl)amide

C19H27NO2 (301.2042)

Ile Ala Val

C14H27N3O4 (301.2001)

Ile Gly Ile

C14H27N3O4 (301.2001)

Val Leu Gly

C14H27N3O4 (301.2001)

Val Ile Ala

C14H27N3O4 (301.2001)

Gly Ile Ile

C14H27N3O4 (301.2001)

Leu Val Gly

C14H27N3O4 (301.2001)

ACMC-20mzy0

C14H27N3O4 (301.2001)

Ile Ile Gly

C14H27N3O4 (301.2001)

Gly Leu Val

C14H27N3O4 (301.2001)

Ile Val Ala

C14H27N3O4 (301.2001)

Gly Val Leu

C14H27N3O4 (301.2001)

Ala Ile Val

C14H27N3O4 (301.2001)

Val Ala Ile

C14H27N3O4 (301.2001)

Leu Gly Val

C14H27N3O4 (301.2001)

Tegaserod

C16H23N5O (301.1903)

D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists A - Alimentary tract and metabolism > A06 - Drugs for constipation > A06A - Drugs for constipation C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist Tegaserod is an orally active serotonin receptor 4 (HTR4; 5-HT4R) agonist and a 5-HT2B receptor antagonist. Tegaserod has pKis of 7.5, 8.4 and 7.0 for human recombinant 5-HT2A, 5-HT2B and 5-HT2C receptors, respectively. Tegaserod causes tumor cell apoptosis, blunts PI3K/Akt/mTOR signaling and decreases S6 phosphorylation. Tegaserod has anti-tumor activity and has the potential for irritable bowel syndrome (IBS) research[1][2][3].

Leu Ala Val

C14H27N3O4 (301.2001)

Ile Leu Gly

C14H27N3O4 (301.2001)

Leu Gly Ile

C14H27N3O4 (301.2001)

Leu Leu Gly

C14H27N3O4 (301.2001)

Ile Gly Leu

C14H27N3O4 (301.2001)

Leu Val Ala

C14H27N3O4 (301.2001)

Pentazocine cis-alcohol

C19H27NO2 (301.2042)

Gly Leu Leu

C14H27N3O4 (301.2001)

Val Ala Leu

C14H27N3O4 (301.2001)

Gly Leu Ile

C14H27N3O4 (301.2001)

Ala Val Leu

C14H27N3O4 (301.2001)

Ala Val Ile

C14H27N3O4 (301.2001)

Cyclohexanone, 4-[1-hydroxy-1-phenyl-3-(1-pyrrolidinyl)propyl]-

C19H27NO2 (301.2042)

Leu Gly Leu

C14H27N3O4 (301.2001)

Leu Ile Gly

C14H27N3O4 (301.2001)

Val Leu Ala

C14H27N3O4 (301.2001)

Ala Leu Val

C14H27N3O4 (301.2001)

Gly Ile Leu

C14H27N3O4 (301.2001)

Leu-Leu-Gly

C14H27N3O4 (301.2001)

A tripeptide composed of two L-leucine units and glycine joined in sequence by peptide linkages.

TERT-BUTYL 3,4-DIHYDRO-2H-SPIRO[NAPHTHALENE-1,4-PIPERIDINE]-1-CARBOXYLATE

C19H27NO2 (301.2042)

mantabegron

C19H27NO2 (301.2042)

(R)-BoroLeu-(+)-Pinanediol-HCl

C15H29BClNO2 (301.198)

(R,R)-3,4-trans-(N-Boc)-diaminopyrrolidine

C14H27N3O4 (301.2001)

3-tributylgermylpropan-1-amine

C15H35GeN (301.199)

1-[[(Z)-[5-(Hydroxymethyl)indol-3-ylidene]methyl]amino]-2-pentylguanidine

C16H23N5O (301.1903)

N-(N-L-Leucylglycyl)-L-leucine

C14H27N3O4 (301.2001)

H-Ala-Val-Leu-OH

C14H27N3O4 (301.2001)

Glycyl-L-leucyl-L-leucine

C14H27N3O4 (301.2001)

(1R,9R,13R)-1,13-Dimethyl-10-[[(2R)-oxolan-2-yl]methyl]-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol

C19H27NO2 (301.2042)

Val-Ala-Leu

C14H27N3O4 (301.2001)

Gly-Ile-Leu

C14H27N3O4 (301.2001)

Ala-Ile-Val

C14H27N3O4 (301.2001)

Leu-Ala-Val

C14H27N3O4 (301.2001)

Ala-Val-Ile

C14H27N3O4 (301.2001)

Ile-Gly-Leu

C14H27N3O4 (301.2001)

Leu-Val-Ala

C14H27N3O4 (301.2001)

Val-Leu-Ala

C14H27N3O4 (301.2001)

Val-Ile-Ala

C14H27N3O4 (301.2001)

Ala-Leu-Val

C14H27N3O4 (301.2001)

Gly-Ile-Ile

C14H27N3O4 (301.2001)

Leu-Ile-Gly

C14H27N3O4 (301.2001)

(1S,7R,8R,14S)-15,17-diazatetracyclo[12.2.2.1(3,7).1(8,12)]icosa-3(20),12(19)-diene-6,9-dione

C18H25N2O2+ (301.1916)

Ile-Ile-Gly

C14H27N3O4 (301.2001)

Ile-Val-Ala

C14H27N3O4 (301.2001)

Val-Ala-Ile

C14H27N3O4 (301.2001)

Gly-Leu-Ile

C14H27N3O4 (301.2001)

Ile-Ala-Val

C14H27N3O4 (301.2001)

Ile-Gly-Ile

C14H27N3O4 (301.2001)

Ile-Leu-Gly

C14H27N3O4 (301.2001)

Leu-Gly-Ile

C14H27N3O4 (301.2001)

2-[(3S)-1-(cyclohexylmethyl)pyrrolidin-3-yl]-6-luoro-1H-benzimidazole

C18H24FN3 (301.1954)

5-[4-(3-Acetamidopropylamino)butylamino]-5-oxopentanoic acid

C14H27N3O4 (301.2001)

5-[3-(4-Acetamidobutylamino)propylamino]-5-oxopentanoic acid

C14H27N3O4 (301.2001)

NA-Cit 8:0

C14H27N3O4 (301.2001)

Ala-Val-Leu

C14H27N3O4 (301.2001)

Gly-Leu-Leu

C14H27N3O4 (301.2001)

Leu-Gly-Leu

C14H27N3O4 (301.2001)

(6e,8e)-12-(pyridin-2-yl)dodeca-6,8-dien-2-yl acetate

C19H27NO2 (301.2042)

(2s,4e,6e)-12-(pyridin-3-yl)dodeca-4,6-dien-2-yl acetate

C19H27NO2 (301.2042)

(2r,6e,8e)-12-(pyridin-2-yl)dodeca-6,8-dien-2-yl acetate

C19H27NO2 (301.2042)

12-(pyridin-3-yl)dodeca-4,6-dien-2-yl acetate

C19H27NO2 (301.2042)

(2e,9z)-n-(2-hydroxy-2-methylpropyl)pentadeca-2,9-dien-12,14-diynimidic acid

C19H27NO2 (301.2042)

(2e,4e)-n-[2-(4-methoxyphenyl)ethyl]deca-2,4-dienimidic acid

C19H27NO2 (301.2042)

n-[2-(2,2-dimethylchromen-6-yl)ethyl]-n,3-dimethylbutanamide

C19H27NO2 (301.2042)

12-(pyridin-2-yl)dodeca-6,8-dien-2-yl acetate

C19H27NO2 (301.2042)

n'-({[(3z)-5-(hydroxymethyl)indol-3-ylidene]methyl}amino)-n-pentylguanidine

C16H23N5O (301.1903)

n-[2-(4-methoxyphenyl)ethyl]deca-2,4-dienimidic acid

C19H27NO2 (301.2042)

n-(2-hydroxy-2-methylpropyl)pentadeca-2,9-dien-12,14-diynimidic acid

C19H27NO2 (301.2042)